| 41.2 -0.98 (-2.32%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 51.66 | 1-year : | 60.33 |
| Resists | First : | 44.22 | Second : | 51.66 |
| Pivot price | 40.97  |
|||
| Supports | First : | 39.12 | Second : | 35.97 |
| MAs | MA(5) : | 42.29 |
MA(20) : | 40.5 |
| MA(100) : | 35.51 |
MA(250) : | 36.75 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 64.4 |
D(3) : | 74.2 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 46 | Low : | 26.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XENE ] has closed below upper band by 45.8%. Bollinger Bands are 25.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.86 - 43.21 | 43.21 - 43.44 |
| Low: | 40.47 - 40.85 | 40.85 - 41.1 |
| Close: | 40.71 - 41.29 | 41.29 - 41.68 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Tue, 21 Oct 2025
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Exploring a 26.68% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Thu, 16 Oct 2025
Xenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of Azetukalner - Quiver Quantitative
Thu, 16 Oct 2025
225,000-Share Option: Xenon Appoints Tucker Kelly as CFO with 30,000 RSUs preparing for topline data - Stock Titan
Sun, 12 Oct 2025
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance
Sat, 11 Oct 2025
Evaluating Xenon Pharmaceuticals (XENE): Is the Current Valuation Justified After Recent Share Price Momentum? - Sahm
Thu, 09 Oct 2025
Is Xenon Pharmaceuticals a Smart Investment After Its New Clinical Trial Partnership? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 7.16e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 6,910 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.155e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 241.6 % |
| Return on Equity (ttm) | -25.6 % |
| Qtrly Rev. Growth | 7.5e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -33.03 |
| EBITDA (p.s.) | -2.15026e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -230 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.25 |
| Price to Cash Flow | 5.69 |
| Dividend | 0 |
| Forward Dividend | 7.71e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|